When genes are expressed at the wrong time or in the wrong amounts, it alters the function of a cell, leading to disease. By developing small-molecule medicines to control gene expression, we aim to make a profound difference in patients’ lives. We are currently developing tamibarotene for genomically defined subsets of MDS and AML patients. These are cancers that have largely eluded other genomics-based approaches.
Tamibarotene for HR-MDS and AML
Tamibarotene (formerly SY-1425) is an oral selective retinoid acid receptor alpha (RARα) agonist in clinical development for genomically defined subsets of patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia.
View ProgramSY-2101
SY-2101 is a novel oral form of arsenic trioxide (ATO) previously in clinical development for patients with acute promyelocytic leukemia.
View ProgramSY-5609
SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor previously in clinical development for patients with pancreatic cancer.
View Program